GlobeNewswire: Idorsia Pharmaceuticals Ltd Contains the last 10 of 300 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:24:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/22/2850739/0/en/Idorsia-thanks-Guy-Braunstein-for-his-years-of-service-as-he-retires.html?f=22&fvtc=4&fvtv=52356Idorsia thanks Guy Braunstein for his years of service as he retires2024-03-22T06:00:00Z<![CDATA[Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development and member of the Idorsia Executive Committee since the creation of Idorsia will retire at the end of March 2024. Guy will continue to support Idorsia as an advisor, especially in the analysis and interpretation of the data coming from the programs that he has initiated and led during his time with the company.]]>https://www.globenewswire.com/news-release/2024/03/22/2850739/0/de/Idorsia-thanks-Guy-Braunstein-for-his-years-of-service-as-he-retires.html?f=22&fvtc=4&fvtv=52356Idorsia thanks Guy Braunstein for his years of service as he retires2024-03-22T06:00:00Z<![CDATA[Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development and member of the Idorsia Executive Committee since the creation of Idorsia will retire at the end of March 2024. Guy will continue to support Idorsia as an advisor, especially in the analysis and interpretation of the data coming from the programs that he has initiated and led during his time with the company.]]>https://www.globenewswire.com/news-release/2024/03/20/2849088/0/en/US-FDA-approves-Idorsia-s-once-daily-TRYVIO-aprocitentan-the-first-and-only-endothelin-receptor-antagonist-for-the-treatment-of-high-blood-pressure-not-adequately-controlled-in-com.html?f=22&fvtc=4&fvtv=52356US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives2024-03-20T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/03/20/2849088/0/de/US-FDA-approves-Idorsia-s-once-daily-TRYVIO-aprocitentan-the-first-and-only-endothelin-receptor-antagonist-for-the-treatment-of-high-blood-pressure-not-adequately-controlled-in-com.html?f=22&fvtc=4&fvtv=52356US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives2024-03-20T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/03/18/2847447/0/en/Idorsia-and-Viatris-successfully-close-the-transaction-for-the-global-research-and-development-collaboration.html?f=22&fvtc=4&fvtv=52356Idorsia and Viatris successfully close the transaction for the global research and development collaboration2024-03-18T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/03/18/2847447/0/de/Idorsia-and-Viatris-successfully-close-the-transaction-for-the-global-research-and-development-collaboration.html?f=22&fvtc=4&fvtv=52356Idorsia and Viatris successfully close the transaction for the global research and development collaboration2024-03-18T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/02/28/2836599/0/en/Idorsia-and-Viatris-enter-into-a-significant-global-research-and-development-collaboration.html?f=22&fvtc=4&fvtv=52356Idorsia and Viatris enter into a significant global research and development collaboration2024-02-28T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/02/28/2836599/0/de/Idorsia-and-Viatris-enter-into-a-significant-global-research-and-development-collaboration.html?f=22&fvtc=4&fvtv=52356Idorsia and Viatris enter into a significant global research and development collaboration2024-02-28T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/01/10/2806804/0/en/Idorsia-presents-at-the-J-P-Morgan-Healthcare-Conference-Adapting-Idorsia-for-sustainable-value-creation.html?f=22&fvtc=4&fvtv=52356Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation2024-01-10T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>https://www.globenewswire.com/news-release/2024/01/10/2806804/0/de/Idorsia-presents-at-the-J-P-Morgan-Healthcare-Conference-Adapting-Idorsia-for-sustainable-value-creation.html?f=22&fvtc=4&fvtv=52356Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation2024-01-10T06:00:00Z<![CDATA[Ad hoc announcement pursuant to Art. 53 LR]]>